Home LiteratureArticle Details
PMID: 17171386 Published · ppublish English Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum.

Magma (New York, N.Y.) ·Vol. 19 ·No. 6 ·2006-12-00 ·Pages 281-96

Mäkinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, Groop PH, Ala-Korpela M, FinnDiane Study Group

Abstract

The most severe complication of type 1 diabetes (T1DM) is diabetic nephropathy. It is associated with a high risk of cardiovascular complications and premature death and requires early detection to be efficiently treated. The clinical practice to diagnose diabetic nephropathy is also a non-optimal and tedious set up based on albumin excretion rate in multiple overnight or 24h urine samples. Conversely, in this study, these independent diagnostic data are used to provide a realistic testing case for applying (1)H NMR metabonomics of serum in a diagnostic fashion. 182 T1DM and 21 non-diabetic (non-T1DM) individuals were studied. The (1)H NMR of serum at 500 MHz was targeted at two molecular windows: lipoprotein lipids and low-molecular-weight metabolites. T1DM and non-T1DM individuals were exclusively separated by (1)H NMR. For diabetic nephropathy diagnosis in the T1DM patients, (1)H NMR data (and clinical biochemistry data) gave a sensitivity of 87.1% (83.9%) and a specificity of 87.7% (95.9%). The predictive values of positive and negative tests were 89.0% (95.5%) and 83.6% (79.2%), respectively. (1)H NMR metabonomics clearly distinguishes metabolic characteristics of T1DM and appears approximately as good a means to diagnose diabetic nephropathy from serum as an advanced set of biochemical variables.

MeSH Terms
Biomarkers/blood Blood Chemical Analysis/methods Blood Proteins/analysis Diabetic Nephropathies/blood,diagnosis Female Humans Magnetic Resonance Spectroscopy/methods Male Proteome/analysis Reproducibility of Results Sensitivity and Specificity
Chemicals
Biomarkers Blood Proteins Proteome
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Mäkinen Ville-Petteri
Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. vmakine2@lce.hut.fi
Soininen Pasi
Forsblom Carol
Parkkonen Maija
Ingman Petri
Kaski Kimmo
Groop Per-Henrik
Ala-Korpela Mika
FinnDiane Study Group
References (46)
46 references, click to expand
  1. Serum lipids and the progression of nephropathy in type 1 diabetes.
    Diabetes Care. 2006 Feb;29(2):317-22 PMID: 16443880
  2. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Atherosclerosis. 2003 Apr;167(2):243-55 PMID: 12818407
  3. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets.
    Anal Chem. 2005 Mar 1;77(5):1282-9 PMID: 15732908
  4. NMR spectral quantitation by principal component analysis.
    NMR Biomed. 2001 Jun;14(4):271-7 PMID: 11410945
  5. Independent component analysis for automated decomposition of in vivo magnetic resonance spectra.
    Magn Reson Med. 2003 Oct;50(4):697-703 PMID: 14523954
  6. Application of self-organizing maps in conformational analysis of lipids.
    J Am Chem Soc. 2001 Feb 7;123(5):810-6 PMID: 11456614
  7. An NMR blood test for cancer: a critical assessment.
    NMR Biomed. 1988 Jun;1(3):136-50 PMID: 3079310
  8. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis.
    Biomarkers. 2004 Jan-Feb;9(1):1-31 PMID: 15204308
  9. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses.
    Metabolism. 2004 Oct;53(10):1296-304 PMID: 15375785
  10. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics.
    Nat Med. 2002 Dec;8(12):1439-44 PMID: 12447357
  11. The role of analytical sciences in medical systems biology.
    Curr Opin Chem Biol. 2004 Oct;8(5):559-65 PMID: 15450501
  12. Sample classification based on Bayesian spectral decomposition of metabonomic NMR data sets.
    Anal Chem. 2004 Jul 1;76(13):3666-74 PMID: 15228339
  13. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.
    N Engl J Med. 1986 Nov 27;315(22):1369-76 PMID: 3022146
  14. Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: a pattern-recognition 1H NMR study.
    NMR Biomed. 2005 Feb;18(1):24-33 PMID: 15455468
  15. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
    Diabetologia. 2003 May;46(5):674-82 PMID: 12743701
  16. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball?
    Philos Trans R Soc Lond B Biol Sci. 2006 Jan 29;361(1465):147-61 PMID: 16553314
  17. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies.
    Anal Chem. 2006 Jan 15;78(2):363-71 PMID: 16408915
  18. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):53-8 PMID: 15556515
  19. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent.
    Atherosclerosis. 2007 Feb;190(2):352-8 PMID: 16730730
  20. Pharmaco-metabonomic phenotyping and personalized drug treatment.
    Nature. 2006 Apr 20;440(7087):1073-7 PMID: 16625200
  21. Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis.
    Clin Infect Dis. 2005 Dec 1;41(11):1582-90 PMID: 16267730
  22. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma.
    J Lipid Res. 1994 Dec;35(12):2292-304 PMID: 7897326
  23. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients.
    Diabetologia. 2003 Oct;46(10):1402-7 PMID: 12928771
  24. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism.
    Nat Rev Drug Discov. 2003 Aug;2(8):668-76 PMID: 12904817
  25. The triglyceride issue revisited. Findings from the Helsinki Heart Study.
    Arch Intern Med. 1994 Dec 12-26;154(23):2714-20 PMID: 7993155
  26. Quantification of biomedical NMR data using artificial neural network analysis: lipoprotein lipid profiles from 1H NMR data of human plasma.
    NMR Biomed. 1995 Sep;8(6):235-44 PMID: 8732179
  27. Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis.
    NMR Biomed. 2000 Aug;13(5):271-88 PMID: 10960918
  28. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition.
    NMR Biomed. 2005 May;18(3):143-62 PMID: 15627238
  29. Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma.
    Anal Biochem. 2004 Feb 15;325(2):260-72 PMID: 14751261
  30. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
    Int J Cancer. 2005 Feb 20;113(5):782-8 PMID: 15499633
  31. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort.
    Invest Ophthalmol Vis Sci. 2004 Mar;45(3):910-8 PMID: 14985310
  32. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).
    Diabetes Care. 2005 Aug;28(8):2019-24 PMID: 16043748
  33. Independent component analysis to proton spectroscopic imaging data of human brain tumours.
    Eur J Radiol. 2005 Nov;56(2):160-4 PMID: 16233889
  34. Metabonomic applications in toxicity screening and disease diagnosis.
    Curr Top Med Chem. 2002 Jan;2(1):35-51 PMID: 11899064
  35. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra.
    Analyst. 2002 Dec;127(12):1549-57 PMID: 12537357
  36. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies.
    Anal Chem. 2005 Jan 15;77(2):517-26 PMID: 15649048
  37. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes.
    Diabetes. 2002 Jun;51(6):1949-56 PMID: 12031985
  38. Type 1 diabetes.
    Lancet. 2006 Mar 11;367(9513):847-58 PMID: 16530579
  39. Proton NMR analysis of plasma is a weak predictor of coronary artery disease.
    Nat Med. 2006 Jun;12(6):705-10 PMID: 16732278
  40. Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism.
    Ann Clin Biochem. 2003 Jan;40(Pt 1):16-24 PMID: 12542907
  41. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
    Diabetes. 2003 Feb;52(2):453-62 PMID: 12540621
  42. Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects.
    Biochem J. 1984 Jan 15;217(2):365-75 PMID: 6696735
  43. A computational strategy for the deconvolution of NMR spectra with multiplet structures and constraints: analysis of overlapping 13C-2H multiplets of 13C enriched metabolites from cell suspensions incubated in deuterated media.
    Magn Reson Med. 1996 Sep;36(3):359-65 PMID: 8875405
  44. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis.
    Anal Chem. 2005 Jul 1;77(13):4108-16 PMID: 15987116
  45. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis.
    Curr Opin Chem Biol. 2003 Oct;7(5):648-54 PMID: 14580571
  46. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
    Diabetes Care. 2003 Mar;26(3):810-8 PMID: 12610042
Article Info
Journal
Magma (New York, N.Y.)
Abbr.
MAGMA
ISSN
0968-5243
DOI
10.1007/s10334-006-0054-y
Email
vmakine2@lce.hut.fi
Published
2006-12-00
Epub
2006-00-15
Pages
281-96
Language
English
Region
Germany
NLM ID
9310752
Subset
IM
External Links
PubMed source DOI: 10.1007/s10334-006-0054-y View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2